Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 170   

Articles published

GSK 1,466.28 -1.72 (-0.12%)
price chart
Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn't want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when ...
GlaxoSmithKline gets 'positive opinion' from EMA panel for three-in-one ...
GlaxoSmithKline plc (LON:GSK) has announced that a European Medicines Agency (EMA) panel has recommended a three-in-one inhaled drug developed with US firm Innoviva, Inc.(NASDAQ: INVA) as a treatment for severe chronic obstructive pulmonary ...
FDA OKs Glaxo's inhaler, first one to combine 3 medicines
This photo provided by GlaxoSmithKline PLC shows the company's Trelegy Ellipta inhaler. Late Monday, Sept. 18, 2017, the Food and Drug Administration approved the product, which is the first inhaler that combines three medicines to ease breathing in ...
Innoviva (INVA) & GlaxoSmithKline Plc (GSK) Granted Approval by FDA for ...  StreetInsider.com
GSK asthma study results published in medical journal and presented at ...
GlaxoSmithKline plc (LON:GSK) said the positive results from its study of asthma treatment, Relvar Eillipta, has been published in The Lancet medical journal and presented at the European Respiratory Society International Congress in Milan.
Why I'd buy this biotechnology star alongside GlaxoSmithKline plc
There's still a youthful growth-investor hidden within me, and I do get tempted by potential future stars from time to time. Right now, I'm looking at the prospects for MaxCyte (LSE: MXCT), which released first-half results Tuesday.
One long-term growth stock I'd buy alongside GlaxoSmithKline plc
It is fair to say that GlaxoSmithKline (LSE: GSK) is not the flavour of the month right now - its share price has rattled 14% lower from the 2017 peak of �17.22 per share struck in June.
The case for GlaxoSmithKline
There are quite a few already-approved drugs in GlaxoSmithKline's lineup that are enjoying rapid sales growth. In 2016, the company claimed seven drugs that posted year-over-year growth of at least 100%.
GlaxoSmithKline plc 11% Potential Upside Indicated by Deutsche Bank
GlaxoSmithKline plc using EPIC/TICKER code (LON:GSK) had its stock rating noted as 'Retains' with the recommendation being set at 'HOLD' today by analysts at Deutsche Bank.
GlaxoSmithKline plc (LON:GSK) Given New GBX 1570 Price Target at JP Morgan ...  The Ledger Gazette
GlaxoSmithKline PLC's (GSK) “Neutral” Rating Reiterated at JP Morgan ...  Week Herald
Freestone Capital Holdings LLC Grows Holdings in GlaxoSmithKline PLC (GSK)
GlaxoSmithKline PLC logo Freestone Capital Holdings LLC increased its position in GlaxoSmithKline PLC (NYSE:GSK) by 11.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).
GlaxoSmithKline plc (LON:GSK) PT Lowered to GBX 1570  AppsforPCdaily
GlaxoSmithKline plc (GSK) Given Hold Rating at Deutsche Bank AG  Newburgh Gazette
Why I've sold this turnaround stock to buy GlaxoSmithKline plc
It has recovered to a large extent during the course of 2017, but now could face a highly uncertain future while lacking a sufficiently wide margin of safety.